| High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam H Periasamy, P Joshi, S Palwe, R Shrivastava, S Bhagwat, M Patel Journal of Antimicrobial Chemotherapy 75 (6), 1650-1651, 2020 | 42 | 2020 |
| In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β … B Moya, IM Barcelo, G Cabot, G Torrens, S Palwe, P Joshi, K Umarkar, ... Antimicrobial Agents and Chemotherapy 63 (5), 10.1128/aac. 00128-19, 2019 | 41 | 2019 |
| Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3 … A Bhatia, M Mastim, M Shah, R Gutte, P Joshi, D Kumbhar, H Periasamy, ... The Journal of the Association of Physicians of India 68 (8), 30-36, 2020 | 26 | 2020 |
| Biochemical role of ascorbic acid during the extraction of nucleic acids in polyphenol rich medicinal plant tissues T Borse, P Joshi, S Chaphalkar Journal of plant molecular biology and biotechnology 2 (2), 1-7, 2011 | 23 | 2011 |
| In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016 … B Appalaraju, S Baveja, S Baliga, S Shenoy, R Bhardwaj, V Kongre, ... Journal of Antimicrobial Chemotherapy 75 (3), 600-608, 2020 | 21 | 2020 |
| Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3 SS Bhagwat, P Hariharan, PR Joshi, SR Palwe, R Shrivastava, MV Patel, ... Journal of Antimicrobial Chemotherapy 75 (12), 3563-3567, 2020 | 18 | 2020 |
| In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals SS Bhagwat, NJ Legakis, T Skalidis, A Loannidis, C Goumenopoulos, ... Diagnostic microbiology and infectious disease 100 (3), 115327, 2021 | 14 | 2021 |
| In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy I Barceló, G Cabot, S Palwe, P Joshi, S Takalkar, H Periasamy, ... Journal of Antimicrobial Chemotherapy 76 (10), 2546-2557, 2021 | 13 | 2021 |
| WCK 5107 (zidebactam, ZID): a pan Gram-negative beta-lactam enhancer augmenting beta-lactam pharmacodynamics in wild type and carbapenemase producers (CP), abstr Sunday-438 SR Palwe, PR Joshi, HN Khande, SS Biniwale, SS Bhagwat, MV Patel ASM Microbe 16, 2016 | 6 | 2016 |
| WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: Activity against ESBL, class C, and KPC-Expressing Enterics and Pseudomonas (PA) Expressing AmpC (PA AmpC) or OXA β … HN Khande, PR Joshi, SR Palwe, SS Bhagwat, MV Patel ASM Microbe 16, 2016 | 6 | 2016 |
| In vitro activity of WCk771, a new benzoquinolizine quinolone in development, against key bacterial groups from the USA and Europe. F-1196 M Hackel, S Bhagwat, H Kanade, P Joshi, M Patel, D Sahm F-1196, 2019 | 5 | 2019 |
| Cefepime (FEP) and WCK 5107 (zidebactam, ZID) mediated dual PBP engagement at sub-MIC concentrations drive cidality against diverse β-lactamase-expressing Gram-negatives SR Palwe, SS Biniwale, HN Khande, PR Joshi, SS Bhagwat, MV Patel ASM Microbe, 2016 | 5 | 2016 |
| WCK 5222 [cefepime (FEP)-WCK 5107 (zidebactam, ZID)]: in vitro and in vivo coverage of OXA-carbapenemases expressing-acinetobacter (OXA-AB) PR Joshi, HN Khande, SS Takalkar, AM Kulkarni, RP Chavan, VS Zope, ... ASM Microbe, 2016 | 5 | 2016 |
| Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases P Joshi, R Shrivastava, S Bhagwat, M Patel Diagnostic microbiology and infectious disease 101 (2), 115481, 2021 | 4 | 2021 |
| Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam AM Hujer, SH Marshall, AR Mack, KM Hujer, YD Bakthavatchalam, ... Mbio 14 (6), e01118-23, 2023 | 2 | 2023 |
| In vitro activity of a novel benzoquinolizine antibiotic, levonadifloxacin (WCK 771) against blood stream gram-positive isolates from a tertiary care hospital D Mamtora, S Saseedharan, R Rampal, P Joshi, P Bhalekar, J Ahdal, ... Journal of Laboratory Physicians 12 (03), 230-232, 2020 | 2 | 2020 |
| Pharmaceutical compositions comprising antibacterial agents S Bhagwat, SR Palwe, PR Joshi, HN Khande, K Umarkar, MV Patel US Patent 10,857,138, 2020 | 1 | 2020 |
| 7-oxo-6-(sulfooxy)-1, 6-diazabicyclo [3.2. 1] octane-2-carboxamide containing compounds and their use in treating bacterial infections VJ Patil, S Shengule, M Pawar, R Bhuniya, ZAB Munshi, PR Joshi, ... US Patent 10,501,464, 2019 | 1 | 2019 |
| Nitrogen containing bicyclic compounds VJ Patil, R Tadiparthi, R Bhuniya, VV Deshmukh, ZAB Munshi, PA Patel, ... US Patent 11,865,108, 2024 | | 2024 |
| Pharmaceutical compositions comprising antibacterial agents MV Patel, S Bhagwat, JS SATAV, HN KHANDE, PR JOSHI, SR PALWE | | 2020 |
